Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

Telomir Pharmaceuticals Inc. (NASDAQ:TELO) on Wednesday announced new preclinical data showing that its lead candidate, ...

Senate Republicans released their version of the Trump administration’s “One Big Beautiful Bill Act” on Monday with a few ...

Circle Pharma receives US FDA orphan drug designation for its CID-078 to treat small cell lung cancer: South San Francisco, California Wednesday, June 18, 2025, 18:00 Hrs [IST] So ...

FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...

New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 ...

A controversial proposal to change the Inflation Reduction Act’s pricing framework for rare disease drugs has been dropped ...

Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa monoclonal antibody, garadacimab (CSL-312), ...

Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA ...

Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 ...